Abstract:This study was aimed at investigating the biodistribution and radioimmunoimaging of I-131-D-D3 in nude mice bearing different types of tumor xenografts. Radioiodination of the D-D3 antibody was performed with the chloramine-T method. The radiochemical purity was determined through thin-layer chromotography. I-131-D-D3 was injected into healthy Kunming mice via a tail vein, and the %ID/g for various organs was obtained. Similarly, the %ID/g and tumor/nontumor tissue ratio of I-131-D-D3 in nude mice bearing small cell lung cancer (SCLC) xenografts were obtained. Planar images of I-131-D-D3 in tumor-bearing nude mice were acquired at different times after injection. The I-131-D-D3 labeling rate was 86.56% +/- 3.8%. The radiochemical purity of I-131-DD3 was 99.27% +/- 0.6%. After 12 hours of incubation in 37 degrees C water bath, the radiochemical purity was 97.64% +/- 0.5% and remained at 88.38% +/- 0.4% after 48 hours. After being mixed with healthy human serum for 24 hours, the radiochemical purity was more than 64%. The metabolism of I-131-D-D3 in healthy Kunming mice was consistent with a two-compartment model with first-order absorption; T-1/2 alpha and T-1/2 beta were 0.25 and 37.89 hours, respectively. The %ID/g of I-131-D-D3 in SCLC xenografts was much higher than those of other tissues at 48 hours after injection, and the tumor/nontumor tissue ratio also gradually increased with time. After 24 hours of injection, planar imaging was obtained, which clearly showed a contrasting tumor on the right armpit of nude mice bearing SCLC with high concentrations of radioactivity. Also, nude mice bearing gastric cancer showed similar results as that of the SCLC with a lower radioactivity level. No observable accumulation was observed in nude mice bearing pancreatic cancer or lung adenocarcinoma. The labeling rate and radiochemical purity of (ID)-I-131-D3 were high and stable. I-131-D-D3 selectively accumulated at tumors that highly expressed progastrin-releasing peptide; therefore, it is a promising radioimmunoimaging reagent for SCLC.

Characteristics in Biodistribution and Metabolism of 131 I Labeled Immunotoxin Against Human Bladder Carcinoma in Tumor-Bearing Nude Mice

Targeted Diagnosis and Treatment of Superficial Bladder Cancer with Monoclonal Antibody BDI-1.

Study on Biodistribution and Radioimmunoimaging of (131)Iodine-Labeled Monoclonal Antibody D-D3 Against Progastrin-Releasing Peptide((31-98)) in Tumor-Bearing Mouse

Biodistribution of ~(131)I-D_2C_5 in nude mice bearing tumor

Comparative Biodistribution of Potential Anti-Glioblastoma Conjugates [111In]dtpa-Hegf and [111In]bz-Dtpa-hegf in Normal Mice

Enhanced Tumor Inhibiting Effect of 131I-Bdi-1-based Radioimmunotherapy and Cytosine Deaminase Gene Therapy Modulated by a Radio-Sensitive Promoter in Nude Mice Bearing Bladder Cancer

Biodistribution and Imaging of Radioiodinate Antihuman Tumor-derived IgG Light Chain Monoclonal Antibody in Nude Mice Bearing Tumor in Vivo

Evaluation of Tumor Vascular Targeting Agents Labelled with 131I in Imaging of Tumor

Radioimmunoimaging and Biodistribution of ~(131)I Labeled Anti-Cea Monoclonal Antibody C50 in Nude Mice Bearing Human Breast Carcinoma Xenografts

Animal experimental study of intratumoral injection using ~(125)I-UdR on human bladder cancer

Experimental Study on the Peptides K237 Radiolabeled with Iodine-~(131) for Targeting Imaging in Nude Mice Bearing Human Prostate Cancer

Clinical Application of Radioimmunoimaging with (99)~m Tc-BDI-1 in the Diagnosis of Bladder Cancer

Radioimmunolocalization and blodistribution of 131Ⅰ labeled anti-CEA,TPS and mixture monoclonal antibody in nude mice bearing human breast cancer xenografts

Studies on distribution and imaging of 131I-labelled RGD peptide in mice bearing tumors

Radioimmunoimaging Diagnosis of Human Bladder Carcinoma.

Biodistribution of iodine-131-labled chimeric monoclonal antibody in patients following intratumoral administraion in advanced lung carcinoma

The Experimental Study of Internal-radiation Therapy in Nude Mice Bearing Orthotopic Bladder Cancer

~(125)I/~(111)in Labeled Anti-EGFR Monoclonal Antibody Panitumumab:Preparation and Biodistribution Evaluation in Normal Mice

Radiolabeling LyP-1 Peptide and Preliminary Biodistribution Evaluation in Mice Bearing MDA-MB-435 Xenografts.

Study on biodistribution of ~(131)iodine labeled monoclonal antibody D-D_3 against pro-gastrin-releasing peptide_((31-98)) in healthy Kunming mice

The experimental study of radioimmunoimaging and radioimmunotherapy using ~(131)I-labeled anti-progastrin-releasing peptide_((31-98)) monoclonal antibody E-B_5